The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Human Chorionic Gonadotropin (HCG)-Global Market Insights and Sales Trends 2025

Human Chorionic Gonadotropin (HCG)-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1822846

No of Pages : 111

Ask Your Query

Synopsis

Human chorionic gonadotropin (HCG) is a female hormone produced by the placenta after implantation of the egg, which is why it can be detected in a few pregnancy tests. In addition, it can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology.

The global Human Chorionic Gonadotropin (HCG) market size is expected to reach US$ 1173.2 million by 2029, growing at a CAGR of 6.6% from 2023 to 2029. The market is mainly driven by the significant applications of Human Chorionic Gonadotropin (HCG) in various end use industries. The expanding demands from the Female Infertility Treatment, Oligospermic Treatment, Cryptorchidism Treatment and Others, are propelling Human Chorionic Gonadotropin (HCG) market. Natural Source Extraction, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Recombinant DNA Technology segment is estimated at % CAGR for the next seven-year period.

The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment. Hypogonadism, for example, is characterized by low serum testosterone concentration, which is followed by a number of clinical features such as erectile dysfunction (ED), poor morning erections, low libido, memory loss, physical decline in strength and health, difficulty concentrating, and depression.According to the study published by BMC Endocrine Disorders in July 2021, erectile dysfunction was found to be prevalent in 72.2% of people globally in 2021. Furthermore, according to the CDC update in March 2022, about 1 in 5 (22%) couples in which the woman is 30-39 have problems conceiving their first child, compared to about 1 in 8 (13%) couples in which the woman is younger than 30. Age-related fertility loss is mostly caused by deteriorating egg quality. Older women also have fewer remaining eggs and are more likely to have health issues that can affect fertility. Aging also increases a woman’s chances of miscarriage and of having a child with a genetic abnormality. Therefore, the high burden of infertility is also raising the demand for effective treatments such as human chorionic gonadotropin (HCG) hormones, which is fueling the market's growth.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Chorionic Gonadotropin (HCG), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Human Chorionic Gonadotropin (HCG) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Human Chorionic Gonadotropin (HCG) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Chorionic Gonadotropin (HCG) sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Human Chorionic Gonadotropin (HCG) covered in this report include EMD Serono, Inc, Ferring B.V, Merck & Co., Inc, Bristol Myers Squibb Company, Fresenius Kabi AG, Scripps Laboratories, Leebio, Kamiya Biomedical Company and Sanzyme, etc.

The global Human Chorionic Gonadotropin (HCG) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • EMD Serono, Inc
  • Ferring B.V
  • Merck & Co., Inc
  • Bristol Myers Squibb Company
  • Fresenius Kabi AG
  • Scripps Laboratories
  • Leebio
  • Kamiya Biomedical Company
  • Sanzyme
  • Cigna
  • LUPIN
  • Sun Pharmaceutical Industries Ltd
  • Serum Institute of India Pvt. Ltd
  • VHB Medi Sciences Limited
  • Zydus Lifesciences Ltd
  • Corona Remedies Pvt. Ltd.

Global Human Chorionic Gonadotropin (HCG) market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Human Chorionic Gonadotropin (HCG) market, Segment by Type:

  • Natural Source Extraction
  • Recombinant DNA Technology

Global Human Chorionic Gonadotropin (HCG) market, by Application:

  • Female Infertility Treatment
  • Oligospermic Treatment
  • Cryptorchidism Treatment
  • Others

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Human Chorionic Gonadotropin (HCG) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index

1 Market Overview of Human Chorionic Gonadotropin (HCG)
1.1 Human Chorionic Gonadotropin (HCG) Market Overview
1.1.1 Human Chorionic Gonadotropin (HCG) Product Scope
1.1.2 Human Chorionic Gonadotropin (HCG) Market Status and Outlook
1.2 Global Human Chorionic Gonadotropin (HCG) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Human Chorionic Gonadotropin (HCG) Market Size by Region (2018-2029)
1.4 Global Human Chorionic Gonadotropin (HCG) Historic Market Size by Region (2018-2023)
1.5 Global Human Chorionic Gonadotropin (HCG) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Human Chorionic Gonadotropin (HCG) Market Size (2018-2029)
1.6.1 North America Human Chorionic Gonadotropin (HCG) Market Size (2018-2029)
1.6.2 Europe Human Chorionic Gonadotropin (HCG) Market Size (2018-2029)
1.6.3 Asia-Pacific Human Chorionic Gonadotropin (HCG) Market Size (2018-2029)
1.6.4 Latin America Human Chorionic Gonadotropin (HCG) Market Size (2018-2029)
1.6.5 Middle East & Africa Human Chorionic Gonadotropin (HCG) Market Size (2018-2029)
2 Human Chorionic Gonadotropin (HCG) Market by Type
2.1 Introduction
2.1.1 Natural Source Extraction
2.1.2 Recombinant DNA Technology
2.2 Global Human Chorionic Gonadotropin (HCG) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Human Chorionic Gonadotropin (HCG) Historic Market Size by Type (2018-2023)
2.2.2 Global Human Chorionic Gonadotropin (HCG) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Type (2018-2029)
3 Human Chorionic Gonadotropin (HCG) Market Overview by Application
3.1 Introduction
3.1.1 Female Infertility Treatment
3.1.2 Oligospermic Treatment
3.1.3 Cryptorchidism Treatment
3.1.4 Others
3.2 Global Human Chorionic Gonadotropin (HCG) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Human Chorionic Gonadotropin (HCG) Historic Market Size by Application (2018-2023)
3.2.2 Global Human Chorionic Gonadotropin (HCG) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Human Chorionic Gonadotropin (HCG) Revenue Breakdown by Application (2018-2029)
4 Human Chorionic Gonadotropin (HCG) Competition Analysis by Players
4.1 Global Human Chorionic Gonadotropin (HCG) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Chorionic Gonadotropin (HCG) as of 2022)
4.3 Date of Key Players Enter into Human Chorionic Gonadotropin (HCG) Market
4.4 Global Top Players Human Chorionic Gonadotropin (HCG) Headquarters and Area Served
4.5 Key Players Human Chorionic Gonadotropin (HCG) Product Solution and Service
4.6 Competitive Status
4.6.1 Human Chorionic Gonadotropin (HCG) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 EMD Serono, Inc
5.1.1 EMD Serono, Inc Profile
5.1.2 EMD Serono, Inc Main Business
5.1.3 EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.1.4 EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.1.5 EMD Serono, Inc Recent Developments
5.2 Ferring B.V
5.2.1 Ferring B.V Profile
5.2.2 Ferring B.V Main Business
5.2.3 Ferring B.V Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.2.4 Ferring B.V Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.2.5 Ferring B.V Recent Developments
5.3 Merck & Co., Inc
5.3.1 Merck & Co., Inc Profile
5.3.2 Merck & Co., Inc Main Business
5.3.3 Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.3.4 Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol Myers Squibb Company Recent Developments
5.4 Bristol Myers Squibb Company
5.4.1 Bristol Myers Squibb Company Profile
5.4.2 Bristol Myers Squibb Company Main Business
5.4.3 Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.4.4 Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol Myers Squibb Company Recent Developments
5.5 Fresenius Kabi AG
5.5.1 Fresenius Kabi AG Profile
5.5.2 Fresenius Kabi AG Main Business
5.5.3 Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.5.4 Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.5.5 Fresenius Kabi AG Recent Developments
5.6 Scripps Laboratories
5.6.1 Scripps Laboratories Profile
5.6.2 Scripps Laboratories Main Business
5.6.3 Scripps Laboratories Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.6.4 Scripps Laboratories Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.6.5 Scripps Laboratories Recent Developments
5.7 Leebio
5.7.1 Leebio Profile
5.7.2 Leebio Main Business
5.7.3 Leebio Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.7.4 Leebio Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.7.5 Leebio Recent Developments
5.8 Kamiya Biomedical Company
5.8.1 Kamiya Biomedical Company Profile
5.8.2 Kamiya Biomedical Company Main Business
5.8.3 Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.8.4 Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.8.5 Kamiya Biomedical Company Recent Developments
5.9 Sanzyme
5.9.1 Sanzyme Profile
5.9.2 Sanzyme Main Business
5.9.3 Sanzyme Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.9.4 Sanzyme Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.9.5 Sanzyme Recent Developments
5.10 Cigna
5.10.1 Cigna Profile
5.10.2 Cigna Main Business
5.10.3 Cigna Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.10.4 Cigna Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.10.5 Cigna Recent Developments
5.11 LUPIN
5.11.1 LUPIN Profile
5.11.2 LUPIN Main Business
5.11.3 LUPIN Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.11.4 LUPIN Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.11.5 LUPIN Recent Developments
5.12 Sun Pharmaceutical Industries Ltd
5.12.1 Sun Pharmaceutical Industries Ltd Profile
5.12.2 Sun Pharmaceutical Industries Ltd Main Business
5.12.3 Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.12.4 Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.12.5 Sun Pharmaceutical Industries Ltd Recent Developments
5.13 Serum Institute of India Pvt. Ltd
5.13.1 Serum Institute of India Pvt. Ltd Profile
5.13.2 Serum Institute of India Pvt. Ltd Main Business
5.13.3 Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.13.4 Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.13.5 Serum Institute of India Pvt. Ltd Recent Developments
5.14 VHB Medi Sciences Limited
5.14.1 VHB Medi Sciences Limited Profile
5.14.2 VHB Medi Sciences Limited Main Business
5.14.3 VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.14.4 VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.14.5 VHB Medi Sciences Limited Recent Developments
5.15 Zydus Lifesciences Ltd
5.15.1 Zydus Lifesciences Ltd Profile
5.15.2 Zydus Lifesciences Ltd Main Business
5.15.3 Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.15.4 Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.15.5 Zydus Lifesciences Ltd Recent Developments
5.16 Corona Remedies Pvt. Ltd.
5.16.1 Corona Remedies Pvt. Ltd. Profile
5.16.2 Corona Remedies Pvt. Ltd. Main Business
5.16.3 Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Products, Services and Solutions
5.16.4 Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Revenue (US$ Million) & (2018-2023)
5.16.5 Corona Remedies Pvt. Ltd. Recent Developments
6 North America
6.1 North America Human Chorionic Gonadotropin (HCG) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Human Chorionic Gonadotropin (HCG) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Human Chorionic Gonadotropin (HCG) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Human Chorionic Gonadotropin (HCG) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Human Chorionic Gonadotropin (HCG) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Human Chorionic Gonadotropin (HCG) Market Dynamics
11.1 Human Chorionic Gonadotropin (HCG) Industry Trends
11.2 Human Chorionic Gonadotropin (HCG) Market Drivers
11.3 Human Chorionic Gonadotropin (HCG) Market Challenges
11.4 Human Chorionic Gonadotropin (HCG) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock